Vernessa T. Pollard
Subscribe to Vernessa T. Pollard's Posts
Vernessa T. Pollard advises companies on regulatory, compliance, enforcement and policy matters involving pharmaceuticals, medical devices, health information technology (HIT) and digital health solutions, services and software. She advises companies and investors on regulatory and compliance issues arising from mergers, acquisitions and other transactions involving Food and Drug Administration (FDA)-regulated products. She also counsels manufacturers, distributors and retailers on regulatory and compliance issues related to food and cosmetic marketing and safety. Read Vernessa Pollard's full bio.
Transformative Healthcare Collaboration Opportunities Emerge from COVID-19 Pandemic
By Stephen Bernstein, Gary Emmanuel, Jennifer S. Geetter, Lisa Schmitz Mazur, Vernessa T. Pollard, Michael Ryan, Joshua Spielman and Kristian Werling on Feb 17, 2021
Posted In Employee Benefits, Health and Welfare Plans, Privacy and Data Security
The seismic, virtually overnight transformation of healthcare delivery as a result of the pandemic has flung open doors to innovation, as a diverse cross-section of digital health and life sciences stakeholders mobilize crisis resources; adjust operations for enhanced screening, sanitization and social distancing measures; harness telehealth capabilities to deliver healthcare remotely; and identify opportunities for...
Continue Reading
Digital Health Year in Review: 2017 Trends and Looking Ahead to 2018
By Jiayan Chen, Lisa Schmitz Mazur, Michael Ryan, Ryan Marcus, Scott Weinstein, Sarah T. Hogan, Vernessa T. Pollard, McDermott Will & Emery, Bernadette M. Broccolo, Dale C. Van Demark and Jennifer S. Geetter on Feb 8, 2018
Posted In Health and Welfare Plans, Privacy and Data Security
Throughout 2017, the health care and life sciences industries experienced a widespread proliferation of digital health innovation that presents challenges to traditional notions of health care delivery and payment as well as product research, development and commercialization for both long-standing and new stakeholders. At the same time, lawmakers and regulators made meaningful progress toward modernizing...
Continue Reading